292 related articles for article (PubMed ID: 11308252)
1. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
[TBL] [Abstract][Full Text] [Related]
2. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
[TBL] [Abstract][Full Text] [Related]
3. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
[TBL] [Abstract][Full Text] [Related]
4. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
5. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
Br J Cancer; 1997; 75(4):602-5. PubMed ID: 9052418
[TBL] [Abstract][Full Text] [Related]
6. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with peri- and postmenopausal bone loss: does HRT prevent weight loss-related bone loss?
Sirola J; Kröger H; Honkanen R; Sandini L; Tuppurainen M; Jurvelin JS; Saarikoski S
Osteoporos Int; 2003 Jan; 14(1):27-33. PubMed ID: 12577182
[TBL] [Abstract][Full Text] [Related]
8. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
[TBL] [Abstract][Full Text] [Related]
9. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
Maddalozzo GF; Widrick JJ; Cardinal BJ; Winters-Stone KM; Hoffman MA; Snow CM
Bone; 2007 May; 40(5):1244-51. PubMed ID: 17291843
[TBL] [Abstract][Full Text] [Related]
10. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women.
Heikkinen AM; Niskanen LK; Salmi JA; Koulu M; Pesonen U; Uusitupa MI; Komulainen MH; Tuppurainen MT; Kröger H; Jurvelin J; Saarikoski S
Bone; 2004 Sep; 35(3):589-94. PubMed ID: 15336593
[TBL] [Abstract][Full Text] [Related]
11. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
Legroux-Gerot I; Vignau J; Collier F; Cortet B
Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
[TBL] [Abstract][Full Text] [Related]
13. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
14. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women.
Gnudi S; Lisi L; Fini M; Malavolta N
Int J Tissue React; 2001; 23(1):33-7. PubMed ID: 11392061
[TBL] [Abstract][Full Text] [Related]
15. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
16. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract][Full Text] [Related]
17. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy.
Filipponi P; Pedetti M; Fedeli L; Cini L; Palumbo R; Boldrini S; Massoni C; Cristallini S
J Bone Miner Res; 1995 May; 10(5):697-703. PubMed ID: 7639104
[TBL] [Abstract][Full Text] [Related]
18. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
19. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
